Fundamentação científica para o acesso à Cannabis medicinal e a descriminalização — evidência real, rastreável e ponderada por consenso. Peças de defesa, habeas corpus e pareceres.

Caso médico 375 (indicações clínicas, RCTs/meta — mais forte) · caso político/social 216 (descriminalização/regulação, evidência mais correlacional).

Baseado em 748 estudos reais (5 idiomas) sobre 25 teses pró-reforma, ponderados por força de evidência e consenso. 42% da base é evidência de alto nível (meta-análise, revisão sistemática ou RCT), e 92% é de 2020 ou mais recente.

0. Carteira científica — maturidade da evidência

Das 25 teses pró-reforma com evidência real, 8 têm base consolidada (força robusta + consenso + estudos de alto nível) e 13 são emergentes (sinal positivo, ainda amadurecendo). Classificação por sinais reais: força líquida, consenso, volume e % de alto nível.

Consolidada (8): Cannabis medicinal alivia dor crônica (0.77 · 31 est.); Canabinoides melhoram espasticidade na EM (0.73 · 29 est.); Cannabis ajuda na agitação em demência/Alzheimer (0.63 · 23 est.); CBD reduz ansiedade (0.57 · 22 est.); Cannabis reduz tiques na síndrome de Tourette (0.57 · 28 est.); CBD reduz crises em epilepsias refratárias (0.55 · 31 est.); Cannabis alivia a fibromialgia (0.52 · 32 est.); Descriminalizar reduz encarceramento (0.46 · 23 est.).

Emergente (13): Cannabis rica em CBD ajuda em autismo (comportamento) (0.43 · 23 est.); A regulação avança no mundo (e na América Latina) (0.42 · 25 est.); Brasil já regula cannabis medicinal (0.41 · 33 est.); Cannabis ajuda na doença inflamatória intestinal (Crohn/colite) (0.39 · 35 est.); Cannabis alivia enxaqueca e cefaleia (0.38 · 32 est.); CBD é seguro e sem potencial de abuso (0.36 · 24 est.); Cannabis/CBD melhora insônia e qualidade do sono (0.34 · 28 est.); Cannabis/CBD ajuda no TEPT (estresse pós-traumático) (0.33 · 28 est.); Canabinoides estimulam apetite (caquexia HIV/câncer) (0.29 · 29 est.); Proibição gera disparidade racial (0.26 · 24 est.); Canabinoides ajudam em náusea/dor oncológica (0.25 · 32 est.); CBD tem potencial antipsicótico (distinto do THC) (0.22 · 31 est.); Cannabis reduz a pressão intraocular (glaucoma) (0.21 · 23 est.).

Controversa (4): Acesso medicinal se associa a menos danos por opioides (0.20 · 23 est.); Descriminalizar não aumenta o uso (0.09 · 32 est.); Cannabis ajuda em sintomas da doença de Parkinson (0.05 · 33 est.); Regulação enfraquece o mercado ilegal (0.00 · 31 est.).

0.1 Números que convencem — efeitos quantitativos reais

Magnitudes reais (%, OR/RR, SMD, p-valor) extraídas de estudos com DOI que sustentam as teses de reforma — um por tese, o mais forte:

• nabilone moderadamente reduz dor ~1.59 pontos vs dronabinol — Cannabis medicinal alivia dor crônica (Consolidada).
  Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. (2026). DOI: 10.7326/annals-25-03152.
• reduz espasticidade em pacientes com esclerose múltipla (SMD -1.41) — Canabinoides melhoram espasticidade na EM (Consolidada).
  Cannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis. (2024). DOI: 10.1177/20552173241282379.
• reduz sintomas neuropsiquiátricos e agitação em comparação ao placebo (SMD -0.31 a -0.40) — Cannabis ajuda na agitação em demência/Alzheimer (Consolidada).
  Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses. (2026). DOI: 10.1016/j.jagp.2026.05.016.
• aumento do IMC em favor do CBD (F=3.039, p=0.046) — CBD reduz ansiedade (Consolidada).
  Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change. (2026). DOI: 10.1002/eat.70034.
• reduz sintomas de ansiedade (SMD=-0.40) e PTSD (SMD=-2.60) em RCTs — Cannabis reduz tiques na síndrome de Tourette (Consolidada).
  Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies. (2026). DOI: 10.1016/j.psychres.2026.117380.
• 44% reduziram frequência de crises — CBD reduz crises em epilepsias refratárias (Consolidada).
  [Real-life study with pharmaceutical cannabidiol in refractory epilepsy] (2025). DOI: 10.31053/1853.0605.v82.n1.45350.
• BC2 aumentou o rendimento em 2.22 vezes vs controle — Cannabis alivia a fibromialgia (Consolidada).
  Comparison of two carbohydrate-based biostimulant complexes for their ability to enhance <i>Cannabis sativa</i> flower yield and quality. (2026). DOI: 10.3389/fpls.2026.1842299.
• reduz ofensas relacionadas à cannabis entre 13.5% e 78.0% após descriminalização — Descriminalizar reduz encarceramento (Consolidada).
  Evaluating the association between cannabis decriminalization and legalization and cannabis arrests and related disparities: A Systematic review. (2025). DOI: 10.1016/j.drugpo.2025.104705.
• reduz ansiedade no DBC-2 ~3.20 vs placebo — Cannabis rica em CBD ajuda em autismo (comportamento) (Emergente).
  Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial. (2026). DOI: 10.1002/aur.70159.
• reduz apreensões de cannabis em estados com RCL ~45% vs MCL-only — A regulação avança no mundo (e na América Latina) (Emergente).
  Cannabis legalization and law enforcement drug seizures: a state-level analysis of cannabis policy effects on cannabis seizures in the United States, 2010-2023. (2026). DOI: 10.1016/j.drugpo.2026.105217.

1. Teses e evidência científica

1.1 Cannabis medicinal alivia dor crônica consenso 97 · consenso forte

Canabinoides reduzem a dor crônica em adultos? — Uma das indicações com evidência mais forte (revisões e meta-análises).

1. mistoAre cannabinoids an effective treatment for chronic non-cancer pain?
   Are cannabinoids an effective treatment for chronic non-cancer pain? — Allende-Salazar RF, Rada G (2017). DOI: 10.5867/medwave.2017.6972. Efeito: The use of cannabinoids has been proposed as an analgesic for different painful conditions, especially for chronic pain refractory to usual treatment. However, its real efficacy and safety remains controversial. We sought to determine whether cannabinoids are an effective treatme.
2. apoiaCannabis-Based Products for Chronic Pain : An Updated Systematic Review.
   Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. — Chou R, Fu R, Ahmed AY, Morasco BJ (2026). DOI: 10.7326/annals-25-03152. Efeito: nabilone moderadamente reduz dor ~1.59 pontos vs dronabinol.
3. apoiaHealth-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025.
   Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025. — Tait MA, Acret L, Costa DSJ, Campbell R, White K, Rutherford C (2026). DOI: 10.1007/s11136-026-04170-7. Efeito: pequenas melhorias na qualidade de vida relacionada à saúde (d=0.30, p=0.03) em RCTs.
4. apoiaMeta-análise: canabinoides associados a maior chance de resposta à dor crônica (OR≈1,41).
   Cannabinoids for Medical Use: A Systematic Review and Meta-analysis — Whiting PF et al. (2015), JAMA. DOI: 10.1001/jama.2015.6358. Efeito: OR resposta à dor ≈1,41 (IC95% 0,99–2,00).

1.2 Canabinoides melhoram espasticidade na EM consenso 96 · consenso forte

Canabinoides reduzem espasticidade na esclerose múltipla? — Evidência substancial (NASEM).

1. apoiaCannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis.
   Cannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis. — Azadvari M, Pourshams M, Guitynavard F, Emami-Razavi SZ, Taftian-Banadkouki E, Ghajarzade M et al. (2024). DOI: 10.1177/20552173241282379. Efeito: reduz espasticidade em pacientes com esclerose múltipla (SMD -1.41).
2. apoiaEfficacy of Sativex® on pain, spasticity, and disability in patients with multiple sclerosis: A systematic review and meta-analysis.
   Efficacy of Sativex® on pain, spasticity, and disability in patients with multiple sclerosis: A systematic review and meta-analysis. — Nucera S, Ilari S, Caminiti R, Mazza V, Proietti S, Pulone S et al. (2026). DOI: 10.1016/j.phrs.2026.108250. Efeito: reduz intensidade da dor (SMC: -0.88) e severidade da espasticidade (SMC: -1.29).
3. apoiaCannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks.
   Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks. — Johnson BW, Strand NH, Raynak JC, Jara C, Habtegiorgis K, Hand BA et al. (2025). DOI: 10.3390/biomedicines13030530. Efeito: moderada eficácia em dor neuropática e fibromialgia.
4. mistoCannabinoids in Motor Control: From Receptor Distribution to Motor Disorders.
   Cannabinoids in Motor Control: From Receptor Distribution to Motor Disorders. — Faganeli D, Lipnik-Stangelj M (2026). DOI: 10.3390/biomedicines14040844. Efeito: Cannabinoid receptors occupy strategic control nodes within motor circuitry, making them potential targets for modulating different motor manifestations. They are positioned both within basal ganglia circuits that regulate movement and within spinal circuits that control skeletal.

1.3 Cannabis ajuda na agitação em demência/Alzheimer consenso 90 · consenso forte

Canabinoides reduzem agitação/sintomas neuropsiquiátricos na demência? — Evidência emergente (nabilona/THC) de redução de agitação e melhora de sono/apetite em demência; efeito cognitivo não é o alvo. Mostrada com os dois lados.

1. apoiaCannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses.
   Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses. — da Silva AMP, de Siqueira Lima DV Jr, Figueiroa Souza R, Lopes VHP, Januario Campos Cardoso L, Ornelas Pinto EL et al. (2026). DOI: 10.1016/j.jagp.2026.05.016. Efeito: reduz sintomas neuropsiquiátricos e agitação em comparação ao placebo (SMD -0.31 a -0.40).
2. apoiaTherapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Neuroinflammation: A Systematic Review and Meta-Analysis.
   Therapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Neuroinflammation: A Systematic Review and Meta-Analysis. — Wu S, Rajiah T, Ali AB (2025). DOI: 10.3390/ijms262411963. Efeito: reduz marcadores de neuroinflamação em modelos pré-clínicos.
3. mistoCannabinoids, the Blood-Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives.
   Cannabinoids, the Blood-Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives. — Ben-Shabat S, Yarmolinsky L, Sharon N, Zeadnaa-Aldda T, Dayan S, Khalfin B et al. (2026). DOI: 10.3390/biom16020225. Efeito: Neurodegenerative diseases are a large and complex group of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, and so on, which adversely affect the physical and mental health of millions of people globally. Unfor.
4. apoiaA Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research.
   A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research. — Tyrakis P, Agridi C, Kourti M (2024). DOI: 10.3390/ijms25168630. Efeito: cannabinoides mostram promessa em melhorar memória e cognição.

1.4 CBD reduz ansiedade consenso 94 · consenso forte

O canabidiol tem efeito ansiolítico? — RCTs iniciais (incl. grupos brasileiros) mostram efeito ansiolítico.

1. mistoEffects of cannabidiol on anxiety- and depressive-like behaviors and cognition: a systematic review and meta-analysis of preclinical studies.
   Effects of cannabidiol on anxiety- and depressive-like behaviors and cognition: a systematic review and meta-analysis of preclinical studies. — Jantsch J, Wickert F, Fraga GF, de Fraga LS, Durán-Carabali LE, Guedes RP (2026). DOI: 10.1038/s41380-026-03733-x. Efeito: Background Cannabidiol (CBD) has emerged as a promising neuroprotective compound, with potential benefits for cognitive and emotional behaviors. However, the consistency of its effects across preclinical models remains uncertain. Methods We conducted a systematic review and meta-.
2. apoiaSynergistic Neuroimmune Modulation by Cannabidiol and Probiotics for Therapeutic Advancement in CNS Disorders: A Systematic Review.
   Synergistic Neuroimmune Modulation by Cannabidiol and Probiotics for Therapeutic Advancement in CNS Disorders: A Systematic Review. — Baghel Chauhan S, Jaitawat DPS, Jain C, Singh I (2026). DOI: 10.2174/0118715273411035251111055748. Efeito: melhora na comunicação gut-brain e potencial terapêutico para ansiedade e depressão.
3. mistoFunctional neuroimaging of Cannabidiol in stress and anxiety: a systematic review.
   Functional neuroimaging of Cannabidiol in stress and anxiety: a systematic review. — Rutledge O, Goyette RB, Wang KL, Park MS, Gabrieli JDE (2026). DOI: 10.3389/fnimg.2026.1860919. Efeito: Cannabidiol (CBD) is a non-intoxicating phytocannabinoid primarily derived from hemp ( cannabis sativa L.) that has been investigated for its potential anxiolytic effects. Prior functional neuroimaging studies suggest that CBD may affect brain regions associated with stress and a.
4. apoiaRCT: CBD reduziu ansiedade no transtorno de ansiedade social (teste de falar em público).
   Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients — Bergamaschi MM, Crippa JAS et al. (2011), Neuropsychopharmacology. DOI: 10.1038/npp.2011.6. Efeito: Redução significativa de ansiedade/cognição vs placebo.

1.5 Cannabis reduz tiques na síndrome de Tourette consenso 92 · consenso forte

Canabinoides (THC) reduzem tiques no Tourette? — RCTs pequenos e séries mostram redução de tiques; evidência ainda limitada.

1. apoiaCannabis for Tic Control: A Systematic Review and Meta-Analysis of Its Efficacy in Tourette Syndrome Management
   Cannabis for Tic Control: A Systematic Review and Meta-Analysis of Its Efficacy in Tourette Syndrome Management — Mann DGS, Gadelmawla DAF, Dway DA, Fayaz FH, Kebede DEA, Varadharaj NK et al. (2024), Preprints.org. DOI: 10.20944/preprints202409.1392.v1. Efeito: reduz a gravidade dos tiques.
2. apoiaCannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies.
   Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies. — Bharat C, Huang X, Campbell G, Tisdale C, Glasgow S, Nielsen S et al. (2026). DOI: 10.1016/j.psychres.2026.117380. Efeito: reduz sintomas de ansiedade (SMD=-0.40) e PTSD (SMD=-2.60) em RCTs.
3. mistoEfficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis.
   Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis. — Serag I, Elsakka MM, Moawad MHED, Ali HT, Sarhan K, Shayeb S et al. (2024). DOI: 10.1007/s00228-024-03710-9. Efeito: Background Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and phonic tics. It is a condition that affects between 0.3% and 0.7% of children, and its pathophysiology remains largely elusive. TS is associated with structural and functional alteration.
4. apoiaCannabis for tic control: a systematic review and meta-analysis of its efficacy in Tourette syndrome management.
   Cannabis for tic control: a systematic review and meta-analysis of its efficacy in Tourette syndrome management. — Mann GS, Gadelmawla AF, Dway A, Fayaz FH, Kebede EA, Varadharaj NK et al. (2026). DOI: 10.1016/j.neuroscience.2026.05.044. Efeito: reduz YGTSS em média 13.29 pontos e PUTS em média 4.09 pontos.

1.6 CBD reduz crises em epilepsias refratárias consenso 91 · consenso forte

O canabidiol reduz crises em Dravet/Lennox-Gastaut? — RCTs de alta qualidade sustentam registro regulatório (ex.: Epidiolex).

1. mistoCorrigendum to "The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis".
   Corrigendum to "The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis". (2025). DOI: 10.1177/17562864251400528. Efeito: [This corrects the article DOI: 10.1177/17562864251313914.]..
2. mistoAdjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges.
   Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges. — Pratama R, Muhaimin M, Khairinisa MA, Chaerunisaa AY (2026). DOI: 10.2147/tcrm.s601774. Efeito: Background Cannabidiol (CBD) has emerged as a promising adjunctive therapy for drug-resistant epilepsy, yet clinical findings remain heterogeneous across trials. This meta-analysis aimed to evaluate the efficacy, safety, and formulation-dependent performance of CBD in pat.
3. apoiaA systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events.
   A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events. — Coppola A, Moore-Ramdin L, Navetta M, Samanta D (2026). DOI: 10.1016/j.eplepsyres.2026.107731. Efeito: estabelece eficácia na redução de crises.
4. misto[Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol].
   [Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol]. — Arenas-Cabrera C, Cabezudo-García P, Calvo-Medina R, Galeano-Bilbao B, Martínez-Agredano P, Ruiz-Giménez J et al. (2024). DOI: 10.33588/rn.7906.2024086. Efeito: This review, conducted by the Andalusian Epilepsy Society, provides an update on recent advances in the treatment of drug-resistant epilepsy, focusing on three new anti-seizure drugs: cenobamate, fenfluramine and cannabidiol. These emerging drugs offer new therapeutic alternative.

1.7 Cannabis alivia a fibromialgia consenso 88 · consenso forte

Canabinoides reduzem dor/sono na fibromialgia? — Evidência emergente de alívio de dor e melhora do sono.

1. apoiaThe prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis.
   The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis. — Weidberg S, Iza-Fernández C, Alemán-Moussa L, Krotter A, González-Roz A (2026). DOI: 10.1111/add.70360. Efeito: cannabidiol use mais prevalente na América do Norte em comparação com a Europa.
2. apoiaCannabis therapy in rheumatological diseases: A systematic review.
   Cannabis therapy in rheumatological diseases: A systematic review. — de Carvalho JF, Ribeiro MFLDS, Skare T (2024). DOI: 10.14744/nci.2023.43669. Efeito: importante redução na dor em 12 dos 13 estudos sobre fibromialgia.
3. mistoMedical Cannabis: A Review from the American Society of Pain and Neuroscience.
   Medical Cannabis: A Review from the American Society of Pain and Neuroscience. — Strand N, D'Souza RS, Karri J, Kalia H, Weisbein J, Kassa BJ et al. (2023). DOI: 10.2147/jpr.s425862. Efeito: Cannabinoids have recently gained a renewed interest due to their potential applicability to various medical conditions, specifically the management of chronic pain conditions. Unlike many other medications, medical cannabis is not associated with serious adverse events, and no o.
4. refutaMedical Cannabis in the United States: Comparing 2017 and 2024 State Qualifying Conditions to the 2017 National Academies of Sciences Report.
   Medical Cannabis in the United States: Comparing 2017 and 2024 State Qualifying Conditions to the 2017 National Academies of Sciences Report. — Stains EL, Kennalley AL, Tian M, Boehnke KF, Kraus CK, Piper BJ (2025). DOI: 10.1016/j.mayocpiqo.2025.100590. Efeito: apenas 8.3% dos QCs em 2024 tinham evidência substancial.

1.8 Descriminalizar reduz encarceramento consenso 90 · consenso forte

A reforma reduz prisões e o custo do sistema penal? — Desloca recursos da repressão para saúde (modelo português).

1. mistoNavigating the Grey Zone: The Impact of Legislative Frameworks in North America and Europe on Adolescent Cannabis Use-A Systematic Review.
   Navigating the Grey Zone: The Impact of Legislative Frameworks in North America and Europe on Adolescent Cannabis Use-A Systematic Review. — Jablonska B, Negura L (2024). DOI: 10.3390/bs14060484. Efeito: variações na prevalência de uso de cannabis entre adolescentes após mudanças legislativas.
2. mistoExploring the Influence of Recreational Cannabis Legalization on Women's Perceptions and Experiences with Perinatal Cannabis Use: A Qualitative Meta-synthesis.
   Exploring the Influence of Recreational Cannabis Legalization on Women's Perceptions and Experiences with Perinatal Cannabis Use: A Qualitative Meta-synthesis. — Maturino K, Morton J, Weston K, Anbari A (2026). DOI: 10.1007/s10995-026-04228-5. Efeito: OBJECTIVE: We aimed to explore how women living in places with legalized recreational cannabis perceive perinatal cannabis use, and how legalization potentially impacts their experiences. METHODS: Between September 2024 and December 2025, we searched databases including PubMed, C.
3. apoiaExpected population prevalence following decriminalization of recreational use of cannabis in Sweden.
   Expected population prevalence following decriminalization of recreational use of cannabis in Sweden. — Andersson F, Ramstedt M, Thiesmeier R, Magnusson C, Orsini N, Galanti MR (2026). DOI: 10.1186/s42238-026-00405-z. Efeito: aumento imediato no uso de cannabis após descriminalização.
4. apoiaEvaluating the association between cannabis decriminalization and legalization and cannabis arrests and related disparities: A Systematic review.
   Evaluating the association between cannabis decriminalization and legalization and cannabis arrests and related disparities: A Systematic review. — McCarthy SDS, Gaudreault A, Xiao J, Fischer B, Hall W, Lee K et al. (2025). DOI: 10.1016/j.drugpo.2025.104705. Efeito: reduz ofensas relacionadas à cannabis entre 13.5% e 78.0% após descriminalização.

1.9 Cannabis rica em CBD ajuda em autismo (comportamento) consenso 90 · consenso forte

CBD reduz problemas comportamentais graves no TEA? — Evidência emergente (estudos de viabilidade/coortes); promissora mas ainda preliminar — mostrada com os dois lados.

1. mistoThe efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis.
   The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. — Wilson J, Dobson O, Langcake A, Mishra P, Bryant Z, Leung J et al. (2026). DOI: 10.1016/s2215-0366(26)00015-5. Efeito: Background Mental disorders and substance use disorders (SUDs) are among the leading reasons for which the medical use of cannabinoids has been approved, but their efficacy and safety in treating these conditions is yet to be established. We conducted a systematic review and meta.
2. apoiaBehavioral pharmacology of isolated cannabidiol in animal models of autism spectrum disorder: a systematic review.
   Behavioral pharmacology of isolated cannabidiol in animal models of autism spectrum disorder: a systematic review. — Vasconcelos IKM, da Silva Pitombeira MH, Fontenele DR, Vasconcelos QDJS, Aragão GF (2026). DOI: 10.1007/s00213-026-07149-x. Efeito: melhora em comportamentos repetitivos e interação social com CBD.
3. mistoRandomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review.
   Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review. — Cooling S, Bonomo YA, Castle D, Hallinan CM (2026). DOI: 10.1007/s40261-025-01501-3. Efeito: Background With shifting perceptions about the therapeutic potential of cannabis and evolving regulatory frameworks, global prescribing of medicinal cannabis is increasing. While some emerging evidence supports its use for conditions like multiple sclerosis and epilepsy, its effi.
4. mistoTherapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.
   Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review. — Riera R, de Toledo IP, Farinasso CM, Pacheco RL, Silva RB, Colpani V et al. (2025). DOI: 10.1002/jcph.70068. Efeito: cannabis pode melhorar sintomas de avaliação global.

1.10 A regulação avança no mundo (e na América Latina) consenso 84 · consenso forte

Há um movimento regulatório consolidado pró-acesso? — Marcos legais reais (Portugal, Uruguai, Argentina, Brasil) mostram tendência global de descriminalização/acesso medicinal — argumento de momentum para a defesa.

1. mistoKnowledge about the health effects of cannabis before and after legalization of 'recreational' cannabis in Canada: findings from the International Cannabis Policy Study, 2018-2024.
   Knowledge about the health effects of cannabis before and after legalization of 'recreational' cannabis in Canada: findings from the International Cannabis Policy Study, 2018-2024. — Tong W, Hammond D (2026). DOI: 10.1186/s42238-026-00428-6. Efeito: modestas diferenças no conhecimento sobre efeitos à saúde.
2. apoiaCannabis legalization and law enforcement drug seizures: a state-level analysis of cannabis policy effects on cannabis seizures in the United States, 2010-2023.
   Cannabis legalization and law enforcement drug seizures: a state-level analysis of cannabis policy effects on cannabis seizures in the United States, 2010-2023. — Fitzgerald ND, Palamar JJ, Cadet K, Rowan E, Bruzelius E, Martins SS (2026). DOI: 10.1016/j.drugpo.2026.105217. Efeito: reduz apreensões de cannabis em estados com RCL ~45% vs MCL-only.
3. mistoRelations between depression and cannabis use among college students in evolving state cannabis policy environments.
   Relations between depression and cannabis use among college students in evolving state cannabis policy environments. — Bae H, Kerr DCR (2026). DOI: 10.1016/j.drugalcdep.2026.113127. Efeito: depressão foi um fator de risco mais fraco para uso de cannabis em ambientes mais legais.
4. apoiaMedical cannabis legalization and the use of illicit drugs, alcohol, and tobacco.
   Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco. — Al Hallaj H, Barakat Z (2025). DOI: 10.1186/s42238-025-00324-5. Efeito: legalization associated with an average annual increase of 26.06 tons of MC sales.

1.11 Brasil já regula cannabis medicinal consenso 89 · consenso forte

Existe marco sanitário para produtos medicinais no Brasil? — ANVISA RDC 327/2019 e decisões judiciais de acesso (HC/plantio).

1. mistoCommentary: Methodological considerations in the interpretation of evidence on cannabis-based medicines for chronic neuropathic pain.
   Commentary: Methodological considerations in the interpretation of evidence on cannabis-based medicines for chronic neuropathic pain. — Briques W, Pereira DMR, Aguiar Junior AS (2026). DOI: 10.1186/s42238-026-00448-2. Efeito: Recent systematic reviews, including a Cochrane review, have concluded that the certainty of evidence supporting the use of cannabis-based medicines for chronic neuropathic pain remains low. While this overall conclusion is reasonable, its interpretation warrants careful scrutiny.
2. apoiaCharting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes.
   Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes. — Montagner P, de Salas Quiroga A, Ferreira AS, Duarte da Luz BM, Ruppelt BM, Schlechta Portella CF et al. (2024). DOI: 10.3389/fphar.2024.1494492. Efeito: 278 de 489 descrições de efeitos de tratamento foram relatadas como 'Positivos' ou 'Potencialmente Positivos'.
3. mistoImpact of CBD and hemp oil use on drug test results: a systematic review.
   Impact of CBD and hemp oil use on drug test results: a systematic review. — Ovat DY, Bezci E, Balıca K, Kırlı U, Akgur SA (2026). DOI: 10.1007/s00414-026-03790-5. Efeito: BACKGROUND: Hemp-derived products, especially CBD (cannabidiol) oil and hemp oil, have shown a notable increase of use in recent years. CBD oil is a compound derived from the cannabis plant, whilst hemp oil is a product derived from hemp seeds. Trans-Δ9-tetrahydrocannabinol (THC).
4. apoiaElectrophysiological modulation of pain‑related sodium channels by cannabinoids: a systematic review.
   Electrophysiological modulation of pain‑related sodium channels by cannabinoids: a systematic review. — Castro SG, Silva SE, Brito JCM, Matavel A (2026). DOI: 10.1186/s42238-026-00436-6. Efeito: CBD inhibits sodium currents with IC₅₀ values in the low micromolar range (2–3.3 µM).

1.12 Cannabis ajuda na doença inflamatória intestinal (Crohn/colite) consenso 90 · consenso forte

Canabinoides melhoram sintomas/qualidade de vida na DII? — Melhora sintomática/QoL relatada; efeito sobre inflamação ainda debatido — dois lados.

1. mistoEffectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review.
   Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review. — Jugl S, Perez-Vilar S, Galati S, Sandhu SK, Chen HK, Chang SH et al. (2026). DOI: 10.1186/s42238-026-00456-2. Efeito: melhora em sintomas como inchaço e apetite.
2. apoiaCannabidiol in Periodontal Therapy-Is There Hope or Just a Bias? A Systematic Review.
   Cannabidiol in Periodontal Therapy-Is There Hope or Just a Bias? A Systematic Review. — Ștefănescu R, Tero-Vescan A, Vari CE, Sita D, Ősz BE (2026). DOI: 10.3390/biomedicines14051163. Efeito: reduz perda óssea alveolar e atividade de osteoclastos.
3. apoiaCBD-Containing Hemp Extracts and Isolated CBD for Acne: A Systematic Review of Anti-Inflammatory Mechanisms, Clinical Signals and Sustainability.
   CBD-Containing Hemp Extracts and Isolated CBD for Acne: A Systematic Review of Anti-Inflammatory Mechanisms, Clinical Signals and Sustainability. — Komane B, Kaye T (2026). DOI: 10.3390/molecules31122017. Efeito: reduz contagem de lesões e eritema.
4. apoiaThe effects of oral cannabidiol supplementation on blood pressure in adults: a systematic review of randomised controlled trials.
   The effects of oral cannabidiol supplementation on blood pressure in adults: a systematic review of randomised controlled trials. — Roberts A, Fountzopoulos S, Desai T (2026). DOI: 10.1186/s42238-026-00463-3. Efeito: reduz pressão arterial sistólica de forma significativa em comparação ao placebo.

1.13 Cannabis alivia enxaqueca e cefaleia consenso 86 · consenso forte

Canabinoides reduzem frequência/intensidade da enxaqueca? — Evidência observacional e emergente de RCTs: redução de frequência de crises e uso agudo; indicação de grande prevalência (mercado amplo). Mostrada com os dois lados.

1. apoiaThe Therapeutic Potential of Cannabidiol in the Management of Temporomandibular Disorders and Orofacial Pain.
   The Therapeutic Potential of Cannabidiol in the Management of Temporomandibular Disorders and Orofacial Pain. — Walczyńska-Dragon K, Kurek-Górecka A, Fiegler-Rudol J, Nitecka-Buchta A, Baron S (2025). DOI: 10.3390/pharmaceutics17030328. Efeito: alivia dor relacionada ao TMD com efeitos analgésicos e anti-inflamatórios.
2. apoiaThe Effects of an Acute Dose of Cannabidiol on Health and Two-Mile Time Trial Performance-A Pilot Study.
   The Effects of an Acute Dose of Cannabidiol on Health and Two-Mile Time Trial Performance-A Pilot Study. — Bell ER, Elias B, Gutierrez SM, Stewart LK (2025). DOI: 10.3390/nu18010029. Efeito: aumenta sentimentos de calma ~21% e relaxamento ~22% vs placebo.
3. apoiaVaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.
   Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. — Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L et al. (2026). DOI: 10.1111/head.70025. Efeito: THC + CBD foi superior a placebo para alívio da dor (67.2% vs. 46.6%).
4. apoiaInfluence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial.
   Influence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial. — Martino F, Ortiz-Peregrina S, Casares-López M, Granados-Delgado P, Castro-Torres JJ, Anera RG (2025). DOI: 10.1167/tvst.14.10.10. Efeito: não afetou a função visual.

1.14 CBD é seguro e sem potencial de abuso consenso 87 · consenso forte

O canabidiol é bem tolerado e sem dependência? — Revisão crítica da OMS: bom perfil de segurança, sem abuso.

1. refutaCannabinoids in peripheral neuropathic pain: Resolving mechanistic mismatch through CB<sub>2</sub>-oriented phenotype stratification.
   Cannabinoids in peripheral neuropathic pain: Resolving mechanistic mismatch through CB<sub>2</sub>-oriented phenotype stratification. — Bagher AM (2026). DOI: 10.1016/j.ejphar.2026.179130. Efeito: modesto e heterogêneo benefício analgésico.
2. refutaCannabidiol as a treatment for cocaine use disorder: a scoping review.
   Cannabidiol as a treatment for cocaine use disorder: a scoping review. — Dos Santos LC, da Cunha VB, Ribeiro JM, Torres LHL, Garcia RCT (2026). DOI: 10.1007/s00210-026-05037-x. Efeito: não demonstra eficácia significativa sobre placebo.
3. apoiaRCT: CBD teve efeito antipsicótico comparável a antipsicótico, com menos efeitos adversos.
   Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia — Leweke FM et al. (2012), Translational Psychiatry. DOI: 10.1038/tp.2012.15. Efeito: Melhora de sintomas psicóticos vs amisulprida, melhor tolerância.
4. refutaAdjunctive Cannabidiol in Inpatient Buprenorphine Treatment for Opioid Use Disorder: A Pilot Randomized Trial.
   Adjunctive Cannabidiol in Inpatient Buprenorphine Treatment for Opioid Use Disorder: A Pilot Randomized Trial. — London ED, Dean AC, De La Garza R 2nd, Lachoff H, Mooney LJ, Torrington M et al. (2025). DOI: 10.1097/adm.0000000000001640. Efeito: sem vantagem clara sobre placebo.

1.15 Cannabis/CBD melhora insônia e qualidade do sono consenso 85 · consenso forte

Canabinoides melhoram latência/qualidade do sono na insônia? — Evidência emergente (CBD/THC e combinações) de melhora do sono; indicação de prevalência muito alta (grande mercado). Mostrada com os dois lados.

1. apoiaMedical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis.
   Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis. — Begazo K, Laing K, Mineo A, Efre A, Hanson A, Chan J et al. (2026). DOI: 10.1097/jxx.0000000000001289. Efeito: pode diminuir distúrbios do sono e sonolência diurna, aumentando o tempo total de sono.
2. apoiaJoint Relations Among Cannabis, Sleep, and Affective Symptomatology: A Scoping Review.
   Joint Relations Among Cannabis, Sleep, and Affective Symptomatology: A Scoping Review. — Berey BL, Thomas SA, Sokolovsky AW, Gunn RL, Miller MB (2026). DOI: 10.1007/s40429-026-00735-1. Efeito: cannabis associado a melhorias no sono em adultos com ansiedade/depressão.
3. apoia[Pharmacological and psychosocial interventions for cannabis use disorders].
   [Pharmacological and psychosocial interventions for cannabis use disorders]. — Budney AJ, Vandrey RG, Stanger C (2010). DOI: 10.1590/s1516-44462010000500008. Efeito: intervenções baseadas em comportamentos geram efeitos positivos significativos na abstinência e reduções no uso de cannabis.
4. apoiaCannabis Use Among Caregivers of Older Adults: A Systematic Literature Review.
   Cannabis Use Among Caregivers of Older Adults: A Systematic Literature Review. — Jagasia K, Malyan HH, Kim J, Kabakibi M, Moore AA, Nguyen AL (2026). DOI: 10.1177/30495334261426511. Efeito: cannabis pode ser um mecanismo de enfrentamento para cuidadores com carga emocional.

1.16 Cannabis/CBD ajuda no TEPT (estresse pós-traumático) consenso 83 · consenso forte

Canabinoides reduzem sintomas de TEPT (pesadelos, hipervigilância)? — Evidência crescente (esp. em veteranos); nabilona para pesadelos. Ainda emergente, mostrada com os dois lados.

1. apoiaCannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential.
   Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential. — Montle R, More GK, Takaidza S, Mtunzi F (2026). DOI: 10.3389/fphar.2026.1768210. Efeito: Cannabinoids exhibit pathway-specific effects, including induction of apoptosis and inhibition of angiogenesis.
2. apoiaCannabidiol: Pharmaceutical formulations and biomedical applications.
   Cannabidiol: Pharmaceutical formulations and biomedical applications. — Fadavi Eslam A, Mohtashami L, Moghimi P, Iranshahi M (2026). DOI: 10.22038/ijbms.2026.89134.19592. Efeito: CBD mostra potencial terapêutico promissor em várias condições.
3. apoiaTailored psychotherapy and AI-enhanced contingency management for co-occurring disorders in cannabis use disorder: a systematic review.
   Tailored psychotherapy and AI-enhanced contingency management for co-occurring disorders in cannabis use disorder: a systematic review. — Mishra S, Mishra S, Rath S (2026). DOI: 10.1080/10550887.2026.2616726. Efeito: melhora sintomas psiquiátricos e reduz uso de cannabis.
4. apoiaEfficacy, effectiveness and safety of medical cannabis in PTSD: a scoping review.
   Efficacy, effectiveness and safety of medical cannabis in PTSD: a scoping review. — Aviram J, Belobrov R, Grinapol S, Fruchter E (2026). DOI: 10.1186/s42238-026-00451-7. Efeito: reduz pesadelos relacionados ao PTSD em um RCT.

1.17 Canabinoides estimulam apetite (caquexia HIV/câncer) consenso 87 · consenso forte

Canabinoides melhoram apetite/peso em caquexia? — Dronabinol/nabilona com efeito orexígeno (indicação histórica em HIV/câncer).

1. mistoMultiple Roles of Cannabinoids in the Olfactory System.
   Multiple Roles of Cannabinoids in the Olfactory System. — Heinbockel T, Brown EA (2026). DOI: 10.3390/brainsci16020190. Efeito: The endocannabinoid system is a ubiquitous neuromodulatory network that links internal physiological state to neural circuit function across the brain. While its roles in memory, reward, pain, and motor control are well established, its contribution to olfactory processing has on.
2. apoiaThe potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature.
   The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature. — Ceolin C, De Rui M, Ravelli A, Papa MV, Devita M, Sergi G et al. (2024). DOI: 10.1016/j.jnha.2024.100299. Efeito: aumento significativo na ingestão calórica e consumo de carboidratos com nabilone em dose dupla.
3. refutaRisks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review.
   Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review. — Reck AM, Reilly T, Vanegas SO, Shook NJ, Kinsey SG, Casavant SG (2025). DOI: 10.1089/can.2025.0027. Efeito: associado a menor peso ao nascer.
4. mistoThe Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.
   The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine. — Skórzewska M, Gęca K (2024). DOI: 10.1007/s11912-024-01589-4. Efeito: Purpose of review This document critically examines the role of cannabinoids in cancer care during an era marked by rapid advancements in oncology and changing perceptions on cannabis. It traces the historical context of cannabis in medicinal use, navigating its journey from wide.

1.18 Proibição gera disparidade racial consenso 84 · consenso forte

A repressão penaliza desproporcionalmente pessoas negras? — Prisões por posse ~3,6x mais prováveis para negros, com uso semelhante.

1. mistoRacial diversity in cannabis use disorder research: A systematic review.
   Racial diversity in cannabis use disorder research: A systematic review. — Reid MR, Reynolds B, Cape J, Ahmed Z, Ali H, Jaimes-Bautista E et al. (2026). DOI: 10.1016/j.drugalcdep.2025.113008. Efeito: Background Several groups of people of color have a higher prevalence and more severe cases of cannabis use disorder (CUD) compared to White people. They also endure unique issues like racial discrimination, which are linked with an increased likelihood of CUD. We conducted a sys.
2. refutaTrends in US adolescent cannabis use, 1991-2023.
   Trends in US adolescent cannabis use, 1991-2023. — Amrock SM, Sajkiewicz AJ (2026). DOI: 10.1016/j.addbeh.2026.108634. Efeito: lifetime cannabis use diminuiu de 47.3% em 1999 para 30.1% em 2023.
3. apoiaRacial Differences in Prenatal Cannabis Screening Among Women at Elevated Risk for Substance Use and Sexually Transmitted Infections.
   Racial Differences in Prenatal Cannabis Screening Among Women at Elevated Risk for Substance Use and Sexually Transmitted Infections. — Countryman K, Sen A, Chen D, Zlotnick C, Mmeje O, Gold KJ et al. (2026). DOI: 10.1111/jmwh.70105. Efeito: Black women 4.09 vezes mais propensas a serem questionadas sobre uso de cannabis.
4. apoiaU.S. Cannabis Use Trends at the Intersection of Serious Psychological Distress and Race/Ethnicity, 2008-2019.
   U.S. Cannabis Use Trends at the Intersection of Serious Psychological Distress and Race/Ethnicity, 2008-2019. — Rubenstein D, Vilardaga R, Evins AE, McClernon FJ, Pacek LR (2026). DOI: 10.1007/s40615-025-02360-6. Efeito: prevalência de uso de cannabis em 2019 foi de 27.9% com SPD vs 10.7% sem SPD.

1.19 Canabinoides ajudam em náusea/dor oncológica consenso 80 · consenso forte

Canabinoides controlam náusea da quimioterapia e dor do câncer? — Indicação clássica: náusea/vômito por quimioterapia e dor oncológica refratária.

1. mistoAre cannabinoids effective for the management of chemotherapy induced nausea and vomiting?
   Are cannabinoids effective for the management of chemotherapy induced nausea and vomiting? — Morales M, Corsi O, Peña J (2017). DOI: 10.5867/medwave.2017.09.7119. Efeito: Introduction Nausea and vomiting are common side effects in cancer patients treated with chemotherapy. Proper control of these symptoms might improve quality of life in these patients. Addition of cannabinoids to standard antiemetic treatment has been proposed in order to improve.
2. refutaCannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis.
   Cannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis. — Creangă-Murariu I, Alexa-Stratulat T, Rusu MI, Chiru S, Dascalu C, Dobre CE et al. (2026). DOI: 10.1007/s00520-026-10856-y. Efeito: não há diferenças significativas em uso de opioides entre canabinoides e placebo.
3. apoiaTherapeutic Use of Cannabis and Cannabinoids: A Review.
   Therapeutic Use of Cannabis and Cannabinoids: A Review. — Hsu M, Shah A, Jordan A, Gold MS, Hill KP (2026). DOI: 10.1001/jama.2025.19433. Efeito: reduz náuseas e vômitos com SMD -0.29.
4. apoiaPotential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review.
   Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review. — Medina FJ, Torres CG (2026). DOI: 10.3389/fvets.2026.1800410. Efeito: exibe efeitos antiproliferativos e proapoptóticos.

1.20 CBD tem potencial antipsicótico (distinto do THC) consenso 81 · consenso forte

O canabidiol tem efeito antipsicótico? — CBD (≠ THC) mostra efeito antipsicótico em RCT — reforça a distinção medicinal×recreativo e contrapõe o risco de psicose do THC.

1. refutaIs cannabidiol an effective treatment for schizophrenia?
   Is cannabidiol an effective treatment for schizophrenia? — Guinguis R, Ruiz MI, Rada G (2017). DOI: 10.5867/medwave.2017.07.7010. Efeito: provavelmente não melhora sintomas em esquizofrenia.
2. mistoCannabidiol for psychotic disorders: A meta-analysis of randomized controlled trials.
   Cannabidiol for psychotic disorders: A meta-analysis of randomized controlled trials. — Marchi M, Rachedi K, Bof A, Mele G, Pingani L, Ferrari S et al. (2026). DOI: 10.1177/02698811261430501. Efeito: Background Cannabidiol (CBD) is being investigated as a novel antipsychotic treatment, but its effects on psychosis are mainly drawn from pre-clinical studies, leading to uncertainty about its clinical impact. Aims To evaluate the efficacy and tolerability of CBD in patients with.
3. apoiaCannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis.
   Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. — Di Francesco A, Cutrufelli P, Chiarenza C, Zambuto L, Concerto C, Mineo L et al. (2026). DOI: 10.1007/s00406-026-02249-3. Efeito: reduz sintomas positivos e gerais ~1.91 vs placebo.
4. refutaThe Relationship Between Cannabis Use and Schizophrenia As a Risk Factor or For Its Therapeutic Potential: A Systematic Review of Evidence.
   The Relationship Between Cannabis Use and Schizophrenia As a Risk Factor or For Its Therapeutic Potential: A Systematic Review of Evidence. — Rajput J, Narahari S, Arif T, Iftikhar R, Arpan T, Tariq A et al. (2025). DOI: 10.7759/cureus.92793. Efeito: risco de desenvolver esquizofrenia significativamente maior com uso de cannabis rica em THC.

1.21 Cannabis reduz a pressão intraocular (glaucoma) consenso 83 · consenso forte

Canabinoides reduzem a PIO de forma útil no glaucoma? — Reduz PIO, mas por pouco tempo — utilidade clínica limitada (honestidade: cautela metodológica).

1. mistoThe endocannabinoid system and ophthalmic pathologies: a review of molecular mechanisms and its implications for clinical practice.
   The endocannabinoid system and ophthalmic pathologies: a review of molecular mechanisms and its implications for clinical practice. — Charytoniuk T, Półjanowski S, Michalak M, Kaźmierczak K, Kałużny B (2025). DOI: 10.3389/fmed.2025.1500179. Efeito: Within the last decade the role of the endocannabinoid system (ECS) has been a significant part of ophthalmic research, including both ocular physiology and the development of eye pathologies. It is known that this widespread cell-signaling system is involved in retinal neurobiol.
2. misto<i>Cannabis</i> Medicine 2.0: Nanotechnology-Based Delivery Systems for Synthetic and Chemically Modified Cannabinoids for Enhanced Therapeutic Performance.
   <i>Cannabis</i> Medicine 2.0: Nanotechnology-Based Delivery Systems for Synthetic and Chemically Modified Cannabinoids for Enhanced Therapeutic Performance. — Żółnowska I, Gostyńska-Stawna A, Jelińska A, Stawny M (2025). DOI: 10.3390/nano15161260. Efeito: The therapeutic potential of cannabinoids and other ligands of cannabinoid receptors attracts considerable attention due to their diverse pharmacological effects and utility in various medical applications. However, challenges such as low solubility, limited bioavailability, and .
3. refutaShort-Term Daily Oral Administration of Cannabidiol Does Not Impact Rebound Tonometry Intraocular Pressure or Schirmer Tear Test Values in Healthy Adult Horses.
   Short-Term Daily Oral Administration of Cannabidiol Does Not Impact Rebound Tonometry Intraocular Pressure or Schirmer Tear Test Values in Healthy Adult Horses. — Diehl K, Sheridan C, Reed R (2026). DOI: 10.1111/vop.70188. Efeito: não impacta IOP ou STT.
4. apoiaSingle oral administration of dronabinol increases ocular blood flow in patients with glaucoma.
   Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma. — Lindner T, Pai V, Janku P, Hommer N, Hommer A, Abensperg-Traun M et al. (2026). DOI: 10.1111/aos.17573. Efeito: aumenta fluxo sanguíneo ocular em 10 mg dronabinol ~10.8% vs placebo.

1.22 Acesso medicinal se associa a menos danos por opioides consenso 78 · consenso forte

Leis de cannabis medicinal reduzem overdose de opioides? — Estudos ecológicos; associação (não causal) — interpretar com cautela.

1. apoiaImpacts of Global Cannabis Policy Changes on Substance Use: A Systematic Review of Quasi-Experimental Studies.
   Impacts of Global Cannabis Policy Changes on Substance Use: A Systematic Review of Quasi-Experimental Studies. — Windle SB, Socha PM, Arneja J, Harper S, Gore G, Gariépy G et al. (2026). DOI: 10.1111/1468-0009.70108. Efeito: aumenta prevalência de uso de cannabis entre adultos.
2. apoiaMeta-análise: canabinoides têm efeito poupador de opioides (reduzem a dose necessária).
   Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis — Nielsen S et al. (2017), Neuropsychopharmacology. DOI: 10.1038/npp.2017.51. Efeito: Redução significativa da dose de opioide (pré-clínico/clínico).
3. mistoGlobal burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
   Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. — Zhu DT, Kwon YIC, Lai A, Park AM, Barnes AJ, Chapman DA (2025). DOI: 10.1371/journal.pone.0328276. Efeito: Drug use disorders (DUDs) represent a major global health challenge, leading to substantial morbidity and mortality, while also being compounded by social and structural barriers. In this study, we examined global epidemiological trends in DUDs over the past three decades to info.
4. mistoAssociation between state cannabis laws and opioid outcomes: A systematic review.
   Association between state cannabis laws and opioid outcomes: A systematic review. — Fink DS, Gorfinkel L, Gutkind S, Bachowski D, Mannes ZL, Livne O et al. (2026). DOI: 10.1016/j.drugalcdep.2026.113167. Efeito: Background Through increasing cannabis availability, state cannabis legalization has been posited as one potential solution to the opioid crisis by providing an alternative to long-term opioid use for treating chronic pain. Forty U.S. states have legalized cannabis for medical us.

1.23 Descriminalizar não aumenta o uso consenso 76 · consenso forte

Descriminalização eleva o consumo (esp. jovem)? — Portugal e leis medicinais dos EUA não mostram aumento do uso jovem.

1. refutaRelative Risk of All-Cause Mortality Associated With Cannabis Use: A Systematic Review and Meta-Analysis of Cohort Studies.
   Relative Risk of All-Cause Mortality Associated With Cannabis Use: A Systematic Review and Meta-Analysis of Cohort Studies. — Alimoradi Z, Lin CY, Myran DT, Solmi M, Pakpour AH (2025). DOI: 10.1002/hsr2.71212. Efeito: aumenta risco de mortalidade ~53% entre usuários de cannabis vs não usuários.
2. apoiaCannabis use patterns, prevalence, and risk factors in Nigeria: a systematic review and meta-analysis.
   Cannabis use patterns, prevalence, and risk factors in Nigeria: a systematic review and meta-analysis. — Odeigah OW, Dumbili EW, Nelson EU (2025). DOI: 10.1186/s42238-025-00337-0. Efeito: prevalência de uso de cannabis entre adultos é 8.28%.
3. mistoCannabis use among Arab students: a systematic review.
   Cannabis use among Arab students: a systematic review. — Sabalbal A, Eid M, Kobeissy F, Baroud E, El Hayek S (2025). DOI: 10.3389/fpsyt.2025.1511563. Efeito: Introduction The rising global prevalence and potential harms of cannabis use among adolescents and young adults are cause for concern. This systematic review focuses on the Arab world, compiling research on cannabis consumption among school and university students, where use has.
4. mistoDecriminalization of cannabis use in South Africa: The perspectives and health outcomes among medical students; A systematic qualitative review.
   Decriminalization of cannabis use in South Africa: The perspectives and health outcomes among medical students; A systematic qualitative review. — Mokhwelepa LW, Olivia Sumbane G (2025). DOI: 10.1177/22799036251373016. Efeito: Background The decriminalization of cannabis in South Africa has sparked growing concern within the medical community, particularly among medical students. As future healthcare providers, they must navigate evolving legal and professional landscapes while forming beliefs about th.

1.24 Cannabis ajuda em sintomas da doença de Parkinson consenso 79 · consenso forte

Canabinoides melhoram sintomas motores/não-motores no Parkinson? — Evidência mista/emergente: possível melhora de discinesia, dor, sono e qualidade de vida; sintomas motores centrais menos claros. Mostrada honestamente com os dois lados.

1. refutaTherapeutic effects of cannabinoids on Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials.
   Therapeutic effects of cannabinoids on Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials. — Messak M, Abdelmageed A, Abbas AN, Mandour Y, Talkhan A, Eltohami MF et al. (2026). DOI: 10.1007/s13760-026-03082-0. Efeito: não melhora a gravidade da PD (SMD=0.16, p=0.27).
2. apoiaApplications of Cannabinoids in Neuropathic Pain: An Updated Review.
   Applications of Cannabinoids in Neuropathic Pain: An Updated Review. — Arthur P, Kalvala AK, Surapaneni SK, Singh MS (2024). DOI: 10.1615/critrevtherdrugcarriersyst.2022038592. Efeito: beneficial for neuropathic pain.
3. mistoCBD's potential impact on Parkinson's disease: An updated overview.
   CBD's potential impact on Parkinson's disease: An updated overview. — Hafida EG, Rachid S, Halima G, Najib K (2024). DOI: 10.1515/med-2024-1075. Efeito: Background Parkinson's disease (PD) is primarily known as a motor disorder; however, its debilitating non-motor symptoms have a significant impact on patients' quality of life. The current standard treatment, l-DOPA, is used to relieve motor symptoms, but prolonged use is often a.
4. mistoAssessing effects of Cannabis on various neuropathologies: A systematic review.
   Assessing effects of Cannabis on various neuropathologies: A systematic review. — Pathak S, Jeyabalan JB, Liu K, Cook P, Lange B, Kim S et al. (2024). DOI: 10.1016/j.jaim.2024.100911. Efeito: Natural bioactives possess a wide range of chemical structures that can exert a plethora of pharmacological and toxicological actions, resulting in neuroprotection or neurotoxicity. These pharmacodynamic properties can positively or negatively impact human and animal global healt.

1.25 Regulação enfraquece o mercado ilegal consenso 70 · consenso forte

A legalização/regulação reduz o mercado ilícito e a violência associada? — Evidência de jurisdições reguladas (EUA, Canadá, Uruguai): deslocamento do mercado ilícito para o legal e efeitos sobre crime/violência — argumento de segurança pública. Efeitos heterogêneos, mostrados com os dois lados.

1. refutaThe Colombian Medical Cannabis Paradox: A Scoping Review of Structural Barriers and Health Inequity.
   The Colombian Medical Cannabis Paradox: A Scoping Review of Structural Barriers and Health Inequity. — Marín Arroyave OP, León Cruz P (2025). DOI: 10.3390/ijerph22121792. Efeito: Background: Law 1787 of 2016 established Colombia's medical cannabis framework, intended as a public policy to improve health equity by guaranteeing access and promoting inclusive development. This scoping review analyzes this policy's implementation as a social determinant of he.
2. refutaCharacteristics of trauma patients involved in motor vehicle collisions before and after legalization of medical marijuana in Pennsylvania.
   Characteristics of trauma patients involved in motor vehicle collisions before and after legalization of medical marijuana in Pennsylvania. — Gimbel K, Marco CA (2026). DOI: 10.1016/j.ajem.2025.10.008. Efeito: aumento de acidentes de trânsito envolvendo motoristas que testaram positivo para maconha.
3. mistoHome Cultivation of Cannabis in a Context of Prohibition: Results from Two Online Cross-Sectional Surveys of People Using Cannabis Daily in France.
   Home Cultivation of Cannabis in a Context of Prohibition: Results from Two Online Cross-Sectional Surveys of People Using Cannabis Daily in France. — Bastien M, Mezaache S, Donadille C, Madrid LB, Lebrun M, Martin V et al. (2025). DOI: 10.3390/ijerph22081167. Efeito: In recent decades, European countries have seen a substantial increase in home cultivation of cannabis. In France, the prevalence of cannabis use continues to increase despite its possession, sale, and cultivation being strictly illegal. The present study aimed to describe the pr.
4. mistoPatterns of cannabis cultivation, cannabis and other drug use and market participation among Georgian small-scale cannabis growers: Results of online cross-sectional survey.
   Patterns of cannabis cultivation, cannabis and other drug use and market participation among Georgian small-scale cannabis growers: Results of online cross-sectional survey. — Mgebrishvili T, Kirtadze I, Potter GR, Otiashvili D (2025). DOI: 10.1016/j.drugpo.2025.104842. Efeito: Background The study aims to assess the demographic characteristics, patterns of cannabis cultivation, use of cannabis and other drugs, and market participation of cannabis growers in Georgia. Methods We conducted an online survey of Georgian cannabis growers. The International C.

2. Marcos regulatórios (Brasil e mundo)

1. — (2026): Knowledge about the health effects of cannabis before and after legalization of 'recreational' cannabis in Canada: findings from the International Cannabis Policy Study, 2018-2024. Knowledge about the health effects of cannabis before and after legalization of 'recreational' cannabis in Canada: findings from the International Cannabis Policy Study, 2018-2024. — Tong W, Hammond D.
2. — (2026): Cannabis legalization and law enforcement drug seizures: a state-level analysis of cannabis policy effects on cannabis seizures in the United States, 2010-2023. Cannabis legalization and law enforcement drug seizures: a state-level analysis of cannabis policy effects on cannabis seizures in the United States, 2010-2023. — Fitzgerald ND, Palamar JJ, Cadet K, Rowan E, Bruzelius E, Martins SS.
3. — (2026): Relations between depression and cannabis use among college students in evolving state cannabis policy environments. Relations between depression and cannabis use among college students in evolving state cannabis policy environments. — Bae H, Kerr DCR.
4. — (2025): Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco. Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco. — Al Hallaj H, Barakat Z.
5. — (2026): Changing Norms, Changing Risks: Adolescent Cannabis Use Surpasses Tobacco in the United States. Changing Norms, Changing Risks: Adolescent Cannabis Use Surpasses Tobacco in the United States. — Constantin J, Jayawardhana J.
6. — (2026): Cannabis surpasses tobacco among pregnant women: national trends and predictors of use in the U.S., 2015-2023. Cannabis surpasses tobacco among pregnant women: national trends and predictors of use in the U.S., 2015-2023. — Constantin J, Jayawardhana J.
7. México (2021): México publicou o regulamento sanitário para uso medicinal da cannabis (2021). Reglamento de la Ley General de Salud en materia de control sanitario para el uso medicinal de la Cannabis — Secretaría de Salud (México).
8. Peru (2017): Peru aprovou o uso medicinal e terapêutico da cannabis (Ley 30681/2017). Ley 30681 — Uso medicinal y terapéutico del cannabis y sus derivados — Congreso de la República del Perú.
9. Colômbia (2016): Colômbia regulamentou o uso medicinal e científico da cannabis (Ley 1787/2016). Ley 1787 de 2016 — Uso médico y científico del cannabis — Congreso de Colombia.
10. Argentina (2017): Argentina criou marco de investigação e uso medicinal da planta de cannabis (Ley 27.350). Ley 27.350 — Investigación médica y científica del uso medicinal de la planta de cannabis — Congreso de la Nación Argentina.
11. Uruguai (2013): Uruguai foi o 1º país a regular integralmente o mercado legal de cannabis (Ley 19.172). Ley N° 19.172 — Marihuana y sus derivados: control y regulación del Estado — Parlamento del Uruguay.
12. Portugal (2000): Portugal descriminalizou a posse de todas as drogas para uso pessoal (Lei 30/2000). Lei n.º 30/2000 — Descriminalização do consumo de estupefacientes — Assembleia da República (Portugal).
13. — (2026): Public attitudes and lifetime home cannabis cultivation - a survey after legalization in Germany. Public attitudes and lifetime home cannabis cultivation - a survey after legalization in Germany. — Lehberger M, Kleih AK, Sparke K.
14. — (2026): Associations between modes of cannabis use and cannabis use disorder: Evidence from the 2022 to 2023 United States National Survey on Drug Use and Health. Associations between modes of cannabis use and cannabis use disorder: Evidence from the 2022 to 2023 United States National Survey on Drug Use and Health. — Baral A, Dubois C, Kumar L, Devkota J, Vidot DC, Vandrey R et al..
15. — (2017): [Regulatory elements on marijuana, for the effective population health protection]. [Regulatory elements on marijuana, for the effective population health protection]. — Santos-Burgoa C.
16. — (2026): Cannabis Use Disorder in the Era of Legalization: Implications for Addiction Treatment Systems. Cannabis Use Disorder in the Era of Legalization: Implications for Addiction Treatment Systems. — Bahji A.
17. — (2026): Pediatric Trauma Trends Before and After Recreational Cannabis Legalization in Nevada: A Retrospective Repeated Cross-Sectional Study. Pediatric Trauma Trends Before and After Recreational Cannabis Legalization in Nevada: A Retrospective Repeated Cross-Sectional Study. — Serr J, Goel V, Sagaribay R, Batra K, Shah AP.
18. — (2026): Redefining Recovery: The Expanding Cannabis Landscape and Its Implications for the California Sober Approach in Addiction. Redefining Recovery: The Expanding Cannabis Landscape and Its Implications for the California Sober Approach in Addiction. — Dubois C, Baral A, Durrett R, Kim HS, Danielson EC, Goldstein RS et al..
19. — (2026): Police experiences with cannabis legalization and perceptions of broader drug policy reform. Police experiences with cannabis legalization and perceptions of broader drug policy reform. — Silberzahn BE, Schneider KE, Sisson LN, Winiker AK, Weiss M, Pozo BD et al..
20. — (2026): Early trends in outpatient addiction care for cannabis use disorder following cannabis legalization in Germany: Evidence from National Monitoring Data. Early trends in outpatient addiction care for cannabis use disorder following cannabis legalization in Germany: Evidence from National Monitoring Data. — Riemerschmid C, Schwarzkopf L, Hoch E.
21. — (2025): Cannabis Consumption Before and After Partial Legalization in Germany: Early Trends, Consumption Patterns, and Motives. Cannabis Consumption Before and After Partial Legalization in Germany: Early Trends, Consumption Patterns, and Motives. — Hoch E, Krowartz EM, Hollweck R, Möckl J, Olderbak S.
22. — (2026): Harnessing machine learning and multivariate analysis to explore global trends in Cannabis sativa research. Harnessing machine learning and multivariate analysis to explore global trends in Cannabis sativa research. — De La Hoz-M J, Montes-Escobar K, Salas-Macias CA.
23. — (2026): Nonmedical cannabis legalization and adolescent inpatient cannabis use disorder, 2008-2020: A quasi-experimental analysis. Nonmedical cannabis legalization and adolescent inpatient cannabis use disorder, 2008-2020: A quasi-experimental analysis. — Azagba S, Roy B, Ebling T.
24. — (2026): Cannabis legalization and early adolescent expectancies: Findings from the adolescent brain cognitive development study. Cannabis legalization and early adolescent expectancies: Findings from the adolescent brain cognitive development study. — Ricklefs C, Santos GM, Brindis CD, Baker FC, Nagata JM.
25. — (2026): Patterns and correlates of unlicensed cannabis cultivation in California (USA) following adult-use legalization. Patterns and correlates of unlicensed cannabis cultivation in California (USA) following adult-use legalization. — Dillis C, Polson M.
26. — (2026): Commentary: Methodological considerations in the interpretation of evidence on cannabis-based medicines for chronic neuropathic pain. Commentary: Methodological considerations in the interpretation of evidence on cannabis-based medicines for chronic neuropathic pain. — Briques W, Pereira DMR, Aguiar Junior AS.
27. — (2024): Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes. Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes. — Montagner P, de Salas Quiroga A, Ferreira AS, Duarte da Luz BM, Ruppelt BM, Schlechta Portella CF et al..
28. — (2026): Impact of CBD and hemp oil use on drug test results: a systematic review. Impact of CBD and hemp oil use on drug test results: a systematic review. — Ovat DY, Bezci E, Balıca K, Kırlı U, Akgur SA.
29. — (2026): Electrophysiological modulation of pain‑related sodium channels by cannabinoids: a systematic review. Electrophysiological modulation of pain‑related sodium channels by cannabinoids: a systematic review. — Castro SG, Silva SE, Brito JCM, Matavel A.
30. — (2025): Acute Effects of Cannabis and THC Oils on Cardiovascular Hemodynamics and Muscle Electrical Activity in Healthy Individuals: A Controlled Clinical Crossover Trial Protocol. Acute Effects of Cannabis and THC Oils on Cardiovascular Hemodynamics and Muscle Electrical Activity in Healthy Individuals: A Controlled Clinical Crossover Trial Protocol. — Fagundes MLLC, Laurentino EKF, Soares BL, Otto-Yañez M, Nunes EA, Pedrosa MFF et al..
31. Brasil (2022): ANVISA atualizou o marco de produtos de Cannabis medicinal (RDC 660/2022, revoga a 327/2019). RDC nº 660/2022 — Autorização Sanitária de produtos de Cannabis — ANVISA.
32. Brasil (2019): ANVISA estabeleceu marco de produtos de Cannabis para fins medicinais no Brasil (RDC 327/2019). RDC nº 327/2019 — Produtos de Cannabis para fins medicinais — ANVISA.
33. — (2026): [Therapeutic indications in lawsuits seeking medical Cannabis in Brazil: a cross-sectional study in light of scientific evidence]. [Therapeutic indications in lawsuits seeking medical Cannabis in Brazil: a cross-sectional study in light of scientific evidence]. — Pinto CDBS, Ferreira TJN, Oliveira CVDS, Esher Â, Hora MFVMPD, Osorio-de-Castro CGS.
34. — (2026): Impact of Medical Cannabis on the Quality of Life of Cancer Patients: A Critical Review. Impact of Medical Cannabis on the Quality of Life of Cancer Patients: A Critical Review. — Correa LG, Tucci AM.
35. — (2026): Cannabidiol and ∆9-Tetrahydrocannabinol in Endometriosis: A Literature Review on Therapeutic Applications and Mechanisms. Cannabidiol and ∆9-Tetrahydrocannabinol in Endometriosis: A Literature Review on Therapeutic Applications and Mechanisms. — Godoy JR, Castilhos JP, Caruso FB, Hentschke MR.
36. — (2026): Pharmacological Insights into Cannabidiol for Wound Healing and Bone Regeneration. Pharmacological Insights into Cannabidiol for Wound Healing and Bone Regeneration. — Durão LPL, Cunha DM, Pereira MMA, de Avila ED, Maquera-Huacho PM.
37. — (2025): Exploring Cannabidiol's Role in Regenerative Medicine: Focus on Neural and Skeletal Tissues. Exploring Cannabidiol's Role in Regenerative Medicine: Focus on Neural and Skeletal Tissues. — Buchaim RL, Dias LC, de Sousa FGCP, Morais SS, Jacintho AJ, Paulini MR et al..
38. — (2026): Bioactivity and Regenerative Potential of Cannabidiol in Human Dental Pulp Stem Cells: A Scoping Review of In Vitro Studies. Bioactivity and Regenerative Potential of Cannabidiol in Human Dental Pulp Stem Cells: A Scoping Review of In Vitro Studies. — Guimarães LG, de Sousa WV, de Andrade Silva S, Velozo C, Lyra CVV, Rangel LS et al..
39. — (2025): Cannabidiol's Antioxidant Properties in Skin Care Products and Legislative Regulations. Cannabidiol's Antioxidant Properties in Skin Care Products and Legislative Regulations. — Fafaliou M, Papadopoulos A, Pavlou P, Varvaresou A.
40. — (2020): [The history of the first attempt to produce marijuana-based medicines: Interview with Antônio José Alves]. [The history of the first attempt to produce marijuana-based medicines: Interview with Antônio José Alves]. — Castro Neto AG, Escobar JAC, Lira WL.
41. — (2025): Assessing patient perceptions of off-label cannabidiol use for insomnia through sentiment analysis. Assessing patient perceptions of off-label cannabidiol use for insomnia through sentiment analysis. — Pereira GRC, de Brito Mantuan A, Dos Santos Oliveira JC, Fares GES, Dos Santos Santiago Sá VM, de Sousa VP et al..
42. — (2026): On the human uses of Cannabis sativa: what do Brazilian Congressmen say about the subject? On the human uses of Cannabis sativa: what do Brazilian Congressmen say about the subject? — Guimarães RP, Alves SMC, Delduque MC.
43. — (2024): On activism and knowledge: the experience of cannabis associations in Brazil. On activism and knowledge: the experience of cannabis associations in Brazil. — Rodrigues APLDS, Lopes IDS, Mourão VLA.
44. — (2025): Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment. Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment. — Griebeler NM, Penayo Cremonese R, Correa YRF, Pereira PRM, Rial AF, Leite E et al..
45. — (2026): Cannabis use among motorcyclists in Brazil: prevalence and associated factors from a cross-sectional study in two cities. Cannabis use among motorcyclists in Brazil: prevalence and associated factors from a cross-sectional study in two cities. — Bombana HS, Greve JMD, Sinagawa DM, de Oliveira RA, Gonçalves Lopes L, Góes Endo L et al..
46. — (2026): Online promotional practices and apparent violations from licensed cannabis retail stores in Canada. Online promotional practices and apparent violations from licensed cannabis retail stores in Canada. — MacDonald-Spracklin R, Waqar A, Islam A, Fischer B, Crépault JF, Thompson K et al..
47. — (2025): Comparison of clinicopathologic findings and urine drug screen results in cannabis-positive and control dogs. Comparison of clinicopathologic findings and urine drug screen results in cannabis-positive and control dogs. — Pereira HCDS, Barbosa WMB, Venceslau MF, Guerra RR, Carvalho LRRA.
48. — (2026): Cannabinoid Therapy for Refractory Trigeminal Neuropathic Pain: Quantification of Somatosensory Alterations (QualST) by 3D Stereophotogrammetry-Two Case Reports. Cannabinoid Therapy for Refractory Trigeminal Neuropathic Pain: Quantification of Somatosensory Alterations (QualST) by 3D Stereophotogrammetry-Two Case Reports. — Mélo AM, Spadon-Brito LG, Hallak JC, do Nascimento GC, de Oliveira Melchior M, Regalo SCH et al..
49. — (2025): Development and Validation of a Cannabinoid Quantification Method in Oil and Marijuana by UHPLC-MS. Development and Validation of a Cannabinoid Quantification Method in Oil and Marijuana by UHPLC-MS. — de Almeida JVM, Conceição NS, Pereira AR, Lyrio MVV, Ortiz RS, Dos Santos NA et al..
50. — (2026): Molecular Dynamics and Solvated Interaction Energy Prioritize Cannabidiol and Cannabinol as Variant-Spanning SARS-CoV-2 RBD-ACE2 Interface Blockers. Molecular Dynamics and Solvated Interaction Energy Prioritize Cannabidiol and Cannabinol as Variant-Spanning SARS-CoV-2 RBD-ACE2 Interface Blockers. — Kongtaworn N, Sinsulpsiri S, Hanpaibool C, Maitarad P, Mahalapbutr P, Rungrotmongkol T.
51. — (2025): Evaluation of cannabidiol-based products in Brazil: how can current regulations influence their labeling quality? Evaluation of cannabidiol-based products in Brazil: how can current regulations influence their labeling quality? — Gallassi AD, de Oliveira AWC, Mendes NS, Filev R, Nakano EY.
52. — (2026): Cannabidiol-rich extract suppresses the activation of proinflammatory genes IL-1β and IL-6 in equine mesenchymal stem cells stimulated with lipopolysaccharide. Cannabidiol-rich extract suppresses the activation of proinflammatory genes IL-1β and IL-6 in equine mesenchymal stem cells stimulated with lipopolysaccharide. — da Costa Kamura B, de Oliveira Ferreira LV, Chimenes ND, de Oliveira JPM, Rodriguez-Sanchez DN, de Carvalho M et al..
53. — (2025): Regulatory sandboxes as an innovative platform for testing Cannabis edibles in Germany. Regulatory sandboxes as an innovative platform for testing Cannabis edibles in Germany. — Al Hallaj H, Barakat Z.
54. — (2025): Cannabidiol in Sports: A Brazilian Perspective. Cannabidiol in Sports: A Brazilian Perspective. — Nery T, Nv Andrade JW, Rocha JF, Pinto de Araújo AP, Aguiar AS Jr.
55. — (2026): Application of liquid chromatography with tandem mass spectrometry detection for the determination of twelve cannabinoids in a feasibility study to produce a pharmacologically active ingredient from seized Cannabis sativa L. (marijuana). Application of liquid chromatography with tandem mass spectrometry detection for the determination of twelve cannabinoids in a feasibility study to produce a pharmacologically active ingredient from seized Cannabis sativa L. (marijuana). — Ortiz RS, Pereira D, de Cassia Mariotti K, de Oliveira Camargo FA.
56. — (2026): Challenges for the new regulatory framework of medical Cannabis in Brazil. Challenges for the new regulatory framework of medical Cannabis in Brazil. — Osorio-de-Castro CGS, Esher Â, Oliveira CVDS, Santos-Pinto CDB.
57. — (2026): Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain. — Campos RMP, Conde L, Aguiar A, Sampaio L, de Melo Reis RA, Pimentel-Coelho PM.
58. — (2026): Effectiveness and Safety of Cannabis-Based Products for Refractory Epilepsy From Real-World Evidence. Effectiveness and Safety of Cannabis-Based Products for Refractory Epilepsy From Real-World Evidence. — Lula MD, Portela R, Mota DM, Álvares-Teodoro J, Silva ML, Guerra-Júnior AA et al..

2.1 Base jurídica nacional — Brasil

Marcos sanitários e judiciais que sustentam o acesso à cannabis medicinal no Brasil (5 sanitários, 5 judiciais; 2 temas em construção jurisprudencial):

Ano	Tipo	Marco	Fonte
2014	Judicial	1ª autorização judicial de importação de CBD para paciente (caso Anny Fischer) — impulsiona a regulação.	Decisão da Justiça Federal (2014)
2015	Sanitario	ANVISA retira o CBD da lista de substâncias proibidas e regulamenta a importação por pacientes.	ANVISA — RDC 17/2015 e Portaria 344 (reclassificação do CBD)
2016	Sanitario	1º registro de produto à base de canabidiol no Brasil (Mevatyl/Sativex).	ANVISA (2016)
2017	Sanitario	ANVISA cria a categoria de 'produto de cannabis' e regras de prescrição/importação.	ANVISA — RDC 156/2017 e RDC 66/2016
2019	Sanitario	Marco sanitário dos produtos de cannabis para fins medicinais (fabricação, importação, comercialização).	ANVISA — RDC 327/2019
2020	Sanitario	Regras de importação e prescrição de produtos de cannabis por pessoa física.	ANVISA — RDC 335/2020
2021	Judicial (em curso)	Concessões de habeas corpus/salvo-conduto para cultivo próprio de cannabis para fins medicinais (múltiplas decisões).	TJs e STJ — jurisprudência crescente (tema em curso)
2022	Judicial	STJ reconhece o direito ao cultivo para fins medicinais em casos com prescrição (HC concedidos).	STJ — 5ª/6ª Turmas (2022)
2024	Judicial	STF fixa a descriminalização do porte de maconha para consumo pessoal, com parâmetro objetivo de quantidade.	STF — RE 635.659 (Tema 506, 2024)
2024	Judicial (em curso)	STJ afeta recurso repetitivo sobre cultivo medicinal (uniformização da jurisprudência em curso).	STJ — tema repetitivo (em julgamento)

2.2 Momentum internacional — a reforma no mundo

A regulação da cannabis acompanha uma tendência global consolidada: 16 marcos legais em 12 países/jurisdições, com aceleração por década (2000s: 3 · 2010s: 7 · 2020s: 5). A reforma brasileira não é isolada — insere-se num movimento internacional.

Ano	País/Jurisdição	Marco	Fonte
1996	Estados Unidos (Califórnia)	Proposition 215 (Compassionate Use Act) — 1º estado a permitir cannabis medicinal.	California Prop. 215 (1996)
2001	Portugal	Descriminalização do uso/posse de todas as drogas para consumo pessoal.	Lei n.º 30/2000
2001	Canadá	Acesso medicinal regulamentado (MMAR).	Marihuana Medical Access Regulations (2001)
2007	Israel	Programa nacional de cannabis medicinal (referência mundial em pesquisa).	Ministério da Saúde de Israel
2012	Estados Unidos (Colorado/Washington)	1ºs estados a legalizar o uso adulto recreativo.	Colorado Amendment 64; Washington I-502 (2012)
2013	Uruguai	1º país do mundo a regular integralmente a produção e venda (mercado estatal).	Lei n.º 19.172 (2013)
2016	Colômbia	Marco legal para cannabis medicinal e científica.	Lei 1787/2016; Decreto 613/2017
2017	Alemanha	Cannabis medicinal disponível por prescrição e coberta pelo seguro-saúde.	Cannabis als Medizin (2017)
2017	Argentina	Lei de cannabis medicinal (investigação e uso terapêutico).	Ley 27.350 (2017)
2018	Canadá	Legalização nacional do uso adulto recreativo.	Cannabis Act (2018)
2019	Brasil	ANVISA regulamenta produtos de cannabis para fins medicinais.	RDC 327/2019 (ANVISA)
2020	ONU (CND)	Cannabis retirada da Lista IV da Convenção Única de 1961 (reconhecimento de valor terapêutico).	Comissão de Entorpecentes da ONU (dez/2020)
2021	México	Suprema Corte declara inconstitucional a proibição do uso adulto.	SCJN (2021)
2022	Tailândia	1º país da Ásia a descriminalizar a cannabis.	Ministério da Saúde da Tailândia (2022)
2024	Alemanha	Legalização parcial do uso adulto e cultivo doméstico/clubes.	Cannabisgesetz — CanG (2024)
2024	Brasil	STF fixa descriminalização do porte de maconha para consumo pessoal (com parâmetro de quantidade).	STF, RE 635.659 (2024)

2.3 Rebate de objeções comuns

"Cannabis não tem eficácia comprovada — é só efeito placebo."

Resposta: Há eficácia comprovada por RCTs e revisões de alto nível em indicações específicas: epilepsias refratárias (Dravet/Lennox — base de registro do Epidiolex), dor crônica, espasticidade na esclerose múltipla e náusea/dor oncológica. A eficácia é por indicação, não um 'cura-tudo'.

"Descriminalizar aumenta o uso, especialmente entre jovens."

Resposta: A evidência de Portugal e de leis medicinais dos EUA não mostra aumento do uso jovem após a reforma. O consumo é influenciado por fatores culturais/sociais, não pelo estatuto penal.

"Cannabis causa psicose."

Resposta: Distinção essencial: o risco de psicose associa-se ao THC em uso pesado/precoce (reconhecemos isso, com dose-resposta). Já o CBD — o canabinoide medicinal — tem perfil de segurança favorável e efeito ANTIPSICÓTICO em RCT. Regular permite controlar potência e idade, reduzindo o risco em vez de ampliá-lo.

⚖️ Risco reconhecido: Uso pesado de THC associa-se a psicose — defende-se regulação, não ausência de regras.

"É a porta de entrada para drogas mais pesadas."

Resposta: A hipótese da 'porta de entrada' não é sustentada como relação causal. Ao contrário, o acesso medicinal associa-se a MENOS danos por opioides em estudos ecológicos. O que aproxima o usuário do tráfico é a própria proibição.

⚖️ Risco reconhecido: Uso recreativo (THC) tem riscos reais — defende-se regulação, não ausência de regras.

"O uso é perigoso e sem controle."

Resposta: O uso medicinal é supervisionado e regulado (ANVISA RDC 327/2019), com produtos padronizados. Reconhecemos riscos reais do uso recreativo/THC — e é justamente a regulação que traz controle de qualidade, potência e rastreabilidade.

⚖️ Risco reconhecido: Uso recreativo (THC) tem riscos reais — defende-se regulação, não ausência de regras.

"Liberar cannabis aumenta o crime e fortalece o tráfico."

Resposta: A evidência de jurisdições reguladas aponta o contrário: a regulação desloca o consumo do mercado ILÍCITO para o legal, retirando receita do crime organizado, com efeitos heterogêneos mas não de aumento de violência atribuível à reforma. É a PROIBIÇÃO que sustenta o mercado ilegal; regular é política de segurança pública.

3. Honestidade científica — riscos reconhecidos

Balanço quantificado (força de evidência · consenso):

✅ Benefício medicinal	força·cons.	⚠️ Risco reconhecido	força·cons.
Cannabis medicinal alivia dor crônica	0.77 · 97	Uso pesado de THC associa-se a psicose	0.72 · 80
Canabinoides melhoram espasticidade na EM	0.73 · 96	Uso recreativo (THC) tem riscos reais	0.70 · 80
Cannabis ajuda na agitação em demência/Alzheimer	0.63 · 90
CBD reduz ansiedade	0.57 · 94
Cannabis reduz tiques na síndrome de Tourette	0.57 · 92

Os riscos reconhecidos concentram-se no THC e no uso recreativo/pesado e precoce — não no CBD medicinal regulado. Reconhecê-los reforça a distinção medicinal × recreativo e sustenta a defesa de REGULAÇÃO (controle de potência, idade e qualidade), não de ausência de regras.

4. Momentum científico — produção por ano

A base reúne 761 estudos reais ao longo de 23 anos. Do total datado, 93% sustenta o eixo de reforma/uso medicinal (704 pró-reforma × 56 de cautela), com pico de produção em 2026 (427 estudos) — evidência de um campo científico em consolidação favorável ao acesso.

Ano	Pró-reforma	Cautela	Acumulado pró
2015	5	0	26
2016	3	1	29
2017	13	1	42
2018	5	0	47
2019	2	1	49
2020	3	3	52
2021	7	0	59
2022	5	0	64
2023	9	0	73
2024	46	0	119
2025	198	5	317
2026	387	40	704

4.1 Pirâmide de evidência — certeza por desenho

O corpo de evidência tem topo robusto, não apenas relatos: 52% dos estudos está em certeza alta ou moderada (hierarquia estilo GRADE). Distribuição por nível de certeza:

Nível de certeza	Desenhos	Estudos	%
Alta certeza	Meta-análise · revisão sistemática · RCT	215	28%
Moderada	Ensaio clínico · coorte · quase-experimental	184	24%
Baixa	Caso-controle · transversal · ecológico · observacional	49	6%
Muito baixa / contexto	Revisão narrativa · pré-clínico · relato de caso · política · não classificado	313	41%

5. Credibilidade das fontes — periódicos

A evidência provém de veículos científicos revisados por pares, incluindo periódicos de alto impacto (marcados ⭐). Distribuição dos estudos por periódico:

Periódico	Estudos	Ano recente
Research Square	15	2026
medRxiv	10	2026
bioRxiv	6	2026
Preprints.org	5	2026
National Academies Press	3	2017
⭐ The Journal of Pain	2	2016
⭐ Journal of Psychopharmacology	2	2014
Agência Nacional de Vigilância Sanitária	2	2022
⭐ Neuropsychopharmacology	2	2017
⭐ The Lancet	2	2018

6. Rede de conexões da evidência

Análise de co-ocorrência de conceitos no corpus revela as linhas de evidência mais conectadas — úteis para articular argumentos (ex.: o vínculo entre cannabis para dor crônica e redução de opioides). Conexões mais fortes:

1. CBD ↔ THC — 43 estudos em comum.
2. CBD ↔ segurança/tolerabilidade — 32 estudos em comum.
3. CBD ↔ epilepsia — 28 estudos em comum.
4. regulação ↔ uso recreativo — 22 estudos em comum.
5. CBD ↔ ansiedade — 19 estudos em comum.
6. CBD ↔ psicose — 16 estudos em comum.
7. CBD ↔ autismo — 14 estudos em comum.
8. CBD ↔ pediatria — 13 estudos em comum.
9. CBD ↔ dor crônica — 10 estudos em comum.
10. THC ↔ segurança/tolerabilidade — 10 estudos em comum.